About the Company
corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LXRX News
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
Lexicon Pharmaceuticals, Inc. LXRX announced data from a new post hoc analysis of its phase III inTandem3 study that ...
Crude Oil Edges Higher; Lexicon Pharmaceuticals Shares Jump
U.S. stocks traded lower midway through trading, with the Dow Jones index dipping over 50 points on Monday. The Dow traded ...
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private investment in public equity ...
Lexicon Pharmaceuticals Inc
Picking the best bond ETF can be hard with so many options available. Here's what the experts suggest focusing on.
Lexicon: Q4 Earnings Snapshot
THE WOODLANDS, Texas — THE WOODLANDS, Texas — Lexicon Pharmaceuticals Inc. (LXRX) on Monday reported a loss of $48.2 million in its fourth quarter. On a per-share basis, the The Woodlands, Texas-based ...
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following the receipt of recent feedback from FDA, it is preparing to ...
Lexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended December 31, 2023 and provided an update on key corporate milestones. "2023 was a pivotal year ...
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
Lexicon Pharmaceuticals, Inc. LXRX announced data from a new post hoc analysis of its phase III inTandem3 study that evaluated sotagliflozin for the treatment of patients with type 1 diabetes and ...
Lexicon: Q4 Earnings Snapshot
THE WOODLANDS, Texas (AP) — THE WOODLANDS, Texas (AP) — Lexicon Pharmaceuticals Inc. (LXRX) on Monday reported a loss of $48.2 million in its fourth quarter. On a per-share basis, the The ...
Loading the latest forecasts...